Premium
Survival outcomes in patients with advanced non‐small cell lung cancer treated with erlotinib: expanded access programme data from B elgium (the TRUST study)
Author(s) -
Van Meerbeeck J.,
Galdermans D.,
Bustin F.,
De Vos L.,
Lechat I.,
Abraham I.
Publication year - 2014
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/ecc.12146
Subject(s) - medicine , erlotinib , rash , lung cancer , stage (stratigraphy) , oncology , adenocarcinoma , cancer , epidermal growth factor receptor , paleontology , biology
Erlotinib has been shown to prolong progression‐free ( PFS ) and overall survival ( OS ) in patients with advanced non‐small cell lung cancer ( NSCLC ). We report here on effectiveness data on the subsample of 261 patients from 40 centres in B elgium involved in the TRUST study. Median age was 63 years. Most (69.0%) were male and current/former smokers (84.7%); with E astern C ooperative O ncology G roup ( ECOG ) performance status ( PS ) of 0 or 1 (74.3%), stage IV disease (75.1%) and adenocarcinoma by histology (54.0%). Erlotinib was administered mainly as second‐ (47.1%) or third‐line treatment (48.3%). Response rate was 6.5%; disease control rate 58.3%. Median PFS was 2.2 months. Better PS ( P = 0.0384), stage IIIB disease ( P = 0.0018) and presence of rash ( P < 0.0001) were associated with longer PFS . OS rates at 1, 2 and 3 years were 26.4%, 10.9% and 6.4% respectively. Median OS was 5.9 months. Female gender ( P = 0.007), better PS ( P < 0.0001), stage IIIB disease ( P = 0.0355) and presence of rash ( P < 0.0001) were associated with longer OS . The findings confirm the therapeutic benefit of erlotinib in a broad range of patients in a sample from a country with a historically high lung cancer morbidity and mortality burden. Several determinants of PFS and OS are identified.